---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-047585"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T20:40:09.369407+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences unveils mitoARCUS program PBGENE-PMM; HBV program on track for 2024 filing

## Summary
- Announced PBGENE-PMM, first mitoARCUS candidate targeting m.3243 primary mitochondrial myopathy; CTA/IND submission targeted for 2025.
- Lead PBGENE-HBV for chronic hepatitis B on track for CTA/IND in 2024; data shows potential to eliminate cccDNA and integrated HBV DNA.
- PBGENE-NVS with Novartis aims for in vivo transgene insertion for sickle cell and beta thalassemia; PBGENE-DMD with Lilly subsidiary excises ~500k base pair dystrophin hot spot.
- Partner iECURE-OTC for OTC deficiency showed >20% gene insertion efficiency at 12 months; CTA/IND submission targeted for 2023.
- Company highlights ARCUS platform advantages: unique cut, size, simplicity enabling viral/mitochondrial genome elimination, gene excision, and insertion.

## SEC filing metadata
- accession: 0000950170-23-047585
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017023047585/0000950170-23-047585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017023047585/dtil-20230912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-047585
- JSON: https://secwatch.observer/filing/0000950170-23-047585.json
- Plain text: https://secwatch.observer/filing/0000950170-23-047585.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.